Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain

Resistance to endocrine therapies remains a significant clinical problem for estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand serie...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasan, Sathish, Nwachukwu, Jerome C., Bruno, Nelson E., Dharmarajan, Venkatasubramanian, Goswami, Devrishi, Kastrati, Irida, Novick, Scott, Nowak, Jason, Cavett, Valerie, Zhou, Hai-Bing, Boonmuen, Nittaya, Zhao, Yuechao, Min, Jian, Frasor, Jonna, Katzenellenbogen, Benita S., Griffin, Patrick R., Katzenellenbogen, John A., Nettles, Kendall W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161551/
https://www.ncbi.nlm.nih.gov/pubmed/27870835
http://dx.doi.org/10.1038/nchembio.2236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161551/
https://www.ncbi.nlm.nih.gov/pubmed/27870835
http://dx.doi.org/10.1038/nchembio.2236

Ejemplares similares